MESO

BEARISH

$14.7 Live

Mesoblast Limited · NASDAQ

Target $35.0 (+138.1%)

$9.88 52W Range $21.5

MESO Mesoblast Limited - Fundamental Analysis

BEARISH

Console Chart News

MESO Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$14.7

Analyst Target

$35.0

+138.1% Upside

52W High

$21.5

52W Low

$9.88

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026

Market cap

$1.92B

P/E

N/A

ROE

-18.2%

Profit margin

-144.3%

Debt/Equity

0.24

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

MESO presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete absence of deterministic value markers like the Graham Number. While revenue growth is explosive (1526.8%), the company suffers from a catastrophic negative gross margin of -35.53%, meaning it loses money on its core product delivery. The valuation is extreme, with a Price-to-Book ratio of 32.96 and a Price-to-Sales ratio of 29.42, indicating the stock is priced for perfection despite consistent quarterly losses over several years.

Key Strengths

Explosive year-over-year revenue growth of 1526.80%

Low Debt-to-Equity ratio (0.24) indicating minimal leverage

Healthy short-term liquidity with a Current Ratio of 1.58

Strong analyst price target ($35.00) suggesting significant pipeline potential

Positive 1-year price performance (+36.9%)

Key Risks

Negative Gross Margin (-35.53%) indicates a fundamentally flawed cost structure

Extreme valuation multiples (P/B 32.96, P/S 29.42) far exceeding industry norms

Chronic lack of profitability with negative earnings across 25 consecutive quarters

Bearish technical trend (0/100) suggesting strong downward momentum

High cash burn implied by a profit margin of -144.33%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative/High Risk

Key drivers: Negative gross margins, Extreme P/B ratio, Consistent EPS losses, Explosive but unproven revenue growth

Confidence

90%

Value

10/100

No Graham Number available; valuation is purely speculative based on future pipeline.

Positives

No standout positives identified.

Watchpoints

P/B of 32.96 is unsustainable
P/S of 29.42 is extremely high
Forward P/E is deeply negative

Future

60/100

Growth is present in top-line revenue but not translating to the bottom line.

Positives

Massive YoY revenue growth
Bullish analyst targets

Watchpoints

Negative operating margins
Lack of earnings growth

Past

20/100

Historical earnings track record is poor across 25 quarters.

Positives

Recent 1Y price recovery

Watchpoints

Long history of EPS misses
Consistent quarterly losses over 6+ years

Health

50/100

Balance sheet is clean (low debt), but operational health is failing.

Positives

Low Debt/Equity
Current Ratio > 1.5

Watchpoints

Piotroski F-Score of 4/9 is only 'stable'
Negative ROE and ROA

Dividend

0/100

Typical for biotech, but provides no safety floor for investors.

Positives

No standout positives identified.

Watchpoints

No dividend paid
No history of payouts

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$14.7

Analyst Target

$35.0

Upside/Downside

+138.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MESO and closest competitors.

Updated 2026-04-13

Company	5Y	3Y	1Y	6M	1M	1W
MESO Mesoblast Limited Primary	-15.5%	+113.7%	+36.9%	-19.0%	+1.0%	-1.1%
GLPG Galapagos NV Peer	-63.1%	-24.7%	+17.3%	-16.1%	-14.0%	-2.9%
AUPH Aurinia Pharmaceuticals Inc. Peer	-22.4%	+77.0%	+81.0%	+62.7%	-10.7%	-2.1%
ATRC AtriCure, Inc. Peer	-33.0%	-7.6%	-3.2%	+24.0%	-3.6%	+0.0%
ADUS Addus HomeCare Corporation Peer	-6.0%	+1.0%	+11.6%	-8.1%	-10.1%	-1.8%

MES

Mesoblast Limited

Primary

-15.5%

+113.7%

+36.9%

-19.0%

+1.0%

-1.1%

GLP

Galapagos NV

Peer

-63.1%

-24.7%

+17.3%

-16.1%

-14.0%

-2.9%

AUP

Aurinia Pharmaceuticals Inc.

Peer

-22.4%

+77.0%

+81.0%

+62.7%

-10.7%

-2.1%

ATR

AtriCure, Inc.

Peer

-33.0%

-7.6%

-3.2%

+24.0%

-3.6%

+0.0%

ADU

Addus HomeCare Corporation

Peer

-6.0%

+1.0%

+11.6%

-8.1%

-10.1%

-1.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-210.0

N/A

32.96

29.42

289.77

-294.48

$1.92B

Profitability

Profit margins and return metrics

Profit Margin -144.33%

Operating Margin -55.16%

Gross Margin -35.53%

ROE -18.22%

ROA -6.16%

Growth

Revenue and earnings growth rates

Revenue Growth +1526.8%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.24

Low debt

Current Ratio

1.58

Good

Quick Ratio

1.35

Good

Cash/Share

$0.1

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Total Assets

$0.8B

Liabilities

$0.2B

Equity

$0.6B

Debt/Equity

0.36x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-08-27

$N/A

2023-08-30

$-0.29

+4.9% surprise

2023-05-25

$-0.25

+22.1% surprise

2023-02-27

$-0.33

-18.6% surprise

Healthcare Sector Comparison

Comparing MESO against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)

Return on Equity (ROE)

-18.22%

This Stock

-86.0%

Sector Avg

-78.8% (Below Avg)

Profit Margin

-144.33%

This Stock

-11.76%

Sector Avg

+1127.4% (Superior)

Debt to Equity

0.24

This Stock

3.51

Sector Avg

-93.3% (Less Debt)

Revenue Growth

1526.8%

This Stock

90.15%

Sector Avg

+1593.6% (Fast Growth)

Current Ratio

1.58

This Stock

3.67

Sector Avg

-56.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
MESO Mesoblast Limited	BEARISH	$1.92B	-	-18.2%	-144.3%	$14.7
GLPG Galapagos NV	NEUTRAL	$1.92B	5.16	10.4%	28.8%	$28.56	Compare
AUPH Aurinia Pharmaceuticals Inc.	NEUTRAL	$1.92B	26.42	20.7%	29.3%	$14.53	Compare
ATRC AtriCure, Inc.	NEUTRAL	$1.94B	-	-6.1%	-5.6%	$39.07	Compare
ADUS Addus HomeCare Corporation	NEUTRAL	$1.88B	19.42	9.3%	6.7%	$101.35	Compare

MESO Mesoblast Limited

BEARISH

Mkt Cap

$1.9B

P/E

ROE

-18.2%

Price

$14.7

Compare with MESO

Compare with MESO

Compare with MESO

ADUS Addus HomeCare...

Compare with MESO

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

2 analysts

Jefferies

2025-11-25

Hold Buy

Past News Coverage

Recent headlines mentioning MESO from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

MESO

MESO Mesoblast Limited - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!